Sun Pharma Advanced Research Co P/E Ratio
Current P/E Ratio
3.98
Low Valuation
Very Low - Potentially undervalued or facing challenges
Sun Pharma Advanced Research Co P/E ratio. Sun Pharma Advanced Research Co (SPARC) P/E ratio is 3.98 (Low), EPS (TTM) ₹47.86, current price ₹191.26 on NSE — Very Low - Potentially undervalued or facing challenges. Also explore SPARC stock price history to track price trends across different timeframes.
Current Valuation Metrics
P/E Ratio
3.98
Current Price
₹191.26
EPS (TTM)
₹47.86
Exchange
NSE
Valuation Signal
Signal
Undervalued
Sector Context
Sector Average
56.45
Sector Median
32.5
Sector Rank
#4 of 199
Sector Percentile
2.0%
Earnings Breakdown (TTM)
TTM EPS
₹49.45
Mar 2026
₹54.27
Jun 2026
₹-0.64
SPARC P/E Ratio — Valuation Signal & Historical Context
Sun Pharma Advanced Research Co P/E 3.98 — signal: Undervalued. Examine SPARC Q4 results for recent quarterly revenue, profit and EPS trends.
- Stock appears undervalued with PE of 3.98, suggesting potential buying opportunity
- Trading at discount to sector average PE of 56.45
SPARC vs Healthcare Peers — P/E Ratio Comparison
Sun Pharma Advanced Research Co P/E 3.98 vs Healthcare average 56.45, median 32.5 — range 2.04–740.29.
Sector Average
56.45
Sector Median
32.5
Lowest P/E
2.04
Highest P/E
740.29
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |
| Shelter Pharma | SHELTER | 6.96 | ₹59 | Low |